{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:20:26Z","timestamp":1788171626962,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010677","name":"National Institute of Health","doi-asserted-by":"publisher","award":["UH3DA041146"],"award-info":[{"award-number":["UH3DA041146"]}],"id":[{"id":"10.13039\/100010677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2019.05.061","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T08:14:01Z","timestamp":1559722441000},"page":"4155-4163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2826-4078","authenticated-orcid":false,"given":"Candy S.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6043-3842","authenticated-orcid":false,"given":"Cody J.","family":"Wenthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim D.","family":"Janda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.05.061_b0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/bs.irn.2016.02.009","article-title":"Animal models and the development of vaccines to treat substance use disorders","volume":"126","author":"Ohia-Nwoko","year":"2016","journal-title":"Int Rev Neurobiol."},{"key":"10.1016\/j.vaccine.2019.05.061_b0010","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1080\/21645515.2016.1212785","article-title":"Biologics to treat substance use disorders: current status and new directions","volume":"12","author":"Pravetoni","year":"2016","journal-title":"Human Vacc Immunother"},{"key":"10.1016\/j.vaccine.2019.05.061_b0015","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bcp.12115","article-title":"Vaccines against stimulants: cocaine and MA","volume":"77","author":"Kosten","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2019.05.061_b0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/erv.13.1","article-title":"Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse","volume":"12","author":"Brimijoin","year":"2013","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2019.05.061_b0025","unstructured":"Centers for Disease Control and Prevention 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes \u2014 United States Surveillance Special Report Centers for Disease Control and Prevention, US Department of Health and Human Services Published August 31, 2018 Accessed [November 11, 2018] from <https:\/\/wwwcdcgov\/drugoverdose\/pdf\/pubs\/2018-cdc-drug-surveillance-reportpdf>."},{"key":"10.1016\/j.vaccine.2019.05.061_b0030","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.05.061_b0035","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/add.12573","article-title":"Efficacy of the nicotine vaccine 3\u2032-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial","volume":"109","author":"Hoogsteder","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.vaccine.2019.05.061_b0040","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0264-410X(01)00425-X","article-title":"Human therapeutic cocaine vaccine: safety and immunogenicity","volume":"20","author":"Kosten","year":"2002","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.05.061_b0045","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.pain.2007.10.014","article-title":"Studying sex and gender differences in pain and analgesia: a consensus report","volume":"132","author":"Greenspan","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.vaccine.2019.05.061_b0050","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/sj.npp.1300096","article-title":"Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol","volume":"28","author":"Negus","year":"2003","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.vaccine.2019.05.061_b0055","first-page":"1370","article-title":"Sex differences in supraspinal morphine analgesia are dependent on genotype","volume":"289","author":"Kest","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2019.05.061_b0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/0091-3057(89)90025-7","article-title":"Opioid receptor upregulation and supersensitivity in mice: effect of morphine sensitivity","volume":"32","author":"Yoburn","year":"1989","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.vaccine.2019.05.061_b0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1289\/ehp.1408202","article-title":"Diversity outbred mice identify population-based exposure thresholds and genetic factors that influence benzene-induced genotoxicity","volume":"123","author":"French","year":"2015","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.vaccine.2019.05.061_b0070","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.7b03334","article-title":"Development of a clinically-viable Heroin vaccine","author":"Bremer","year":"2017","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.vaccine.2019.05.061_b0075","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1021\/acs.molpharmaceut.7b00933","article-title":"Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality","volume":"15","author":"Hwang","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2019.05.061_b0080","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/mp400631w","article-title":"Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy","volume":"11","author":"Bremer","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2019.05.061_b0085","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.1073\/pnas.1219159110","article-title":"Dynamic vaccine blocks relapse to compulsive intake of heroin","volume":"110","author":"Schlosburg","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2019.05.061_b0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jat\/33.7.345","article-title":"Determination of heroin and its main metabolites in small sample volumes of whole blood and brain tissue by reversed-phase liquid chromatography-tandem mass spectrometry","volume":"33","author":"Karinen","year":"2009","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.vaccine.2019.05.061_b0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bmc.2018.11.027","article-title":"Heat shock proteins: a dual carrier-adjuvant for an anti-drug vaccine against heroin","volume":"27","author":"Hwang","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.vaccine.2019.05.061_b0100","article-title":"Lateral flow assessment and unanticipated toxicity of Kratom","author":"Smith","year":"2018","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.vaccine.2019.05.061_b0105","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/acs.bioconjchem.5b00085","article-title":"Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers","volume":"26","author":"Jalah","year":"2015","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.vaccine.2019.05.061_b0110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/acs.jmedchem.7b01427","article-title":"A stable Heroin analogue that can serve as a vaccine hapten to induce antibodies that block the effects of heroin and its metabolites in rodents and that cross-react immunologically with related drugs of abuse","volume":"61","author":"Sulima","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.vaccine.2019.05.061_b0115","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.vaccine.2013.04.027","article-title":"Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs","volume":"31","author":"Matyas","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.061_b0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0006-8993(90)90821-R","article-title":"Simultaneous development of opioid tolerance and opioid antagonist-induced receptor upregulation","volume":"529","author":"Yoburn","year":"1990","journal-title":"Brain Res"},{"key":"10.1016\/j.vaccine.2019.05.061_b0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/15476910801897920","article-title":"Adverse consequences of immunostimulation","volume":"5","author":"Ponce","year":"2008","journal-title":"J Immunotoxicol"},{"key":"10.1016\/j.vaccine.2019.05.061_b0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol. Biol Rev: MMBR"},{"key":"10.1016\/j.vaccine.2019.05.061_b0135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/eci.09.31","article-title":"Monoclonal antibody-induced cytokine-release syndrome","volume":"5","author":"Bugelski","year":"2009","journal-title":"Exp Rev Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.05.061_b0140","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0531-5565(00)00226-6","article-title":"Interleukin-1\u03b2 induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease","volume":"36","author":"Hoozemans","year":"2001","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.vaccine.2019.05.061_b0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.nbd.2011.08.007","article-title":"Neuromodulatory role of endogenous interleukin-1\u03b2 in acute seizures: possible contribution of cyclooxygenase-2","volume":"45","author":"Claycomb","year":"2012","journal-title":"Neurobiol Disease"},{"key":"10.1016\/j.vaccine.2019.05.061_b0150","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acschemneuro.8b00079","article-title":"Efficacious Vaccine against Heroin Contaminated with Fentanyl","volume":"9","author":"Hwang","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.vaccine.2019.05.061_b0155","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/anie.201511654","article-title":"Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of Fentanyl Class Drugs","volume":"55","author":"Bremer","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.vaccine.2019.05.061_b0160","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1021\/acschemneuro.6b00389","article-title":"Influencing antibody-mediated attenuation of methamphetamine CNS distribution through vaccine linker design","volume":"8","author":"Gooyit","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.vaccine.2019.05.061_b0165","article-title":"An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life","author":"Kimishima","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2019.05.061_b0170","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/WNR.0000000000000551","article-title":"Tolerance to the antinociceptive and hypothermic effects of morphine is mediated by multiple isoforms of c-Jun N-terminal kinase","volume":"27","author":"Yuill","year":"2016","journal-title":"NeuroReport"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1930698X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1930698X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T03:45:03Z","timestamp":1569210303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1930698X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":34,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X1930698X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}